The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

Immune checkpoint blockade has become standard treatment for many types of cancer.
Such therapy is indicated most often in patients with advanced or metastatic disease but has …

Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies,
including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and …

Immune checkpoint inhibitors (ICIs) have now been approved in numerous and diverse
cancer types and combination regimens. Effective recognition and treatment of ICI toxicities …

Immunotherapy has transformed the treatment landscape for a wide range of human
cancers. Immune checkpoint inhibitors (ICIs), monoclonal antibodies that block the immune …

Immune checkpoint inhibitors (ICIs) have improved the treatment of several cancers. These
drugs increase T-cell activity and the antitumor immune response but also have immune …

Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events
(irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not …

Background Immune-related colitis is a common, often serious complication of immune
checkpoint inhibition (ICI). Although endoscopy is not strictly recommended for any grade of …

Immune-related adverse events (IrAEs) affecting the gastrointestinal (GI) tract and liver are
among the most frequent and most severe inflammatory toxicities from contemporary …